Optimal Duration of Consolidation Durvalumab Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer: A Multi-institutional Retrospective Study: Duration of Durvalumab Following CCRT in Stage III NSCLC: H. Doi et al.
| Publicado en: | Targeted Oncology Vol. 20; no. 1; pp. 161 - 170 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Jan2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=182471355&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 182471355 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 17762596 47DQ jtl: Targeted Oncology issn: 17762596 maglogo: N pubinfo: dt: Jan2025 vid: 20 iid: 1 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 182471355 180715033 10.1007/s11523-024-01105-5 182471355 ppf: 161 ppct: 9 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Optimal Duration of Consolidation Durvalumab Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer: A Multi-institutional Retrospective Study: Duration of Durvalumab Following CCRT in Stage III NSCLC: H. Doi et al. aug: au: Doi, Hiroshi Matsuo, Yukinori Kishi, Noriko Ogura, Masakazu Mitsuyoshi, Takamasa Ueki, Nami Ueki, Kazuhito Fujii, Kota Sakamoto, Masato Atsuta, Tomoko Katagiri, Tomohiro Sakamoto, Takashi Narabayashi, Masaru Ohtsu, Shuji Fujishiro, Satsuki Kishi, Takahiro Mizowaki, Takashi affil: https://ror.org/05kt9ap64 Department of Radiation Oncology, Faculty of Medicine, Kindai University, 377-2 Ohno-Higashi, 589-8511, Osaka-Sayama, Osaka, Japan sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|